TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia
Brief Summary: The primary purpose of this study was to assess the overall safety of different dose regimens of AMG0001 (HGF transferred via plasmid vector) as well as evaluate the improvement of blood perfusion in subjects with critical limb ischemia (CLI). This study also evaluated the improvement in wound healing without adverse effects on the quality of life, as well as the potential reduction of amputation, mortality and rest pain in the CLI population.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Genetic: HGF plasmid | Intervention Type: GENETIC; Name: HGF plasmid; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: MESENDO; Type: EXPERIMENTAL; Interventions: Biological: MESENDO | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MESENDO; Assigned to Arm(s): MESENDO | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia
Brief Summary: The primary purpose of this study was to assess the overall safety of different dose regimens of AMG0001 (HGF transferred via plasmid vector) as well as evaluate the improvement of blood perfusion in subjects with critical limb ischemia (CLI). This study also evaluated the improvement in wound healing without adverse effects on the quality of life, as well as the potential reduction of amputation, mortality and rest pain in the CLI population.


Options:
A: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Genetic: HGF plasmid | Intervention Type: GENETIC; Name: HGF plasmid; Assigned to Arm(s): 1, 2, 3, 4
C: Arm Label: Neovasculgen®; Type: EXPERIMENTAL; Interventions: Drug: Neovasculgen® | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neovasculgen® | Intervention Type: DRUG; Name: Neovasculgen®; Assigned to Arm(s): Neovasculgen®, standard care
D: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Middle Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (Placebo Control) | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Middle Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): High Dose | Intervention Type: OTHER; Name: Saline (Placebo Control); Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder
Brief Summary: The purpose of this study is to determine the safety and effectiveness of Depakote ER compared to placebo in the treatment of bipolar disorder, manic or mixed type in adults.


Options:
A: Intervention Type: DRUG; Name: Divalproex Sodium (Depakote ER); Assigned to Arm(s): N/A
B: Arm Label: Lithium (LI); Type: EXPERIMENTAL; Interventions: Drug: Lithium (LI) | Arm Label: Divalproex (DV); Type: EXPERIMENTAL; Interventions: Drug: Divalproex (DV) | Intervention Type: DRUG; Name: Lithium (LI); Assigned to Arm(s): Lithium (LI) | Intervention Type: DRUG; Name: Divalproex (DV); Assigned to Arm(s): Divalproex (DV)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Divalproex | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: divalproex sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke
Brief Summary: This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.


Options:
A: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
B: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
C: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke
Brief Summary: This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.


Options:
A: Arm Label: Cerebrolysin + donepezil; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + donepezil | Arm Label: Cerebrolysin + placebo; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + placebo | Arm Label: Donepezil + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil + placebo | Intervention Type: DRUG; Name: Cerebrolysin + donepezil; Assigned to Arm(s): Cerebrolysin + donepezil | Intervention Type: DRUG; Name: Cerebrolysin + placebo; Assigned to Arm(s): Cerebrolysin + placebo | Intervention Type: DRUG; Name: Donepezil + placebo; Assigned to Arm(s): Donepezil + placebo
B: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
C: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
D: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke
Brief Summary: This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.


Options:
A: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
C: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke
Brief Summary: This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
D: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Pediatric CI Therapy
Brief Summary: Pediatric Constraint-Induced (CI) Movement therapy is a rehabilitation program designed to improve motor function in children with partial paralysis. Children with cerebral palsy may have one arm that has significantly greater function (good arm) than the other (bad arm). Restricting the use of the good arm may improve the use of the bad arm. In pediatric CI therapy, the good arm is put in a sling to force increased use of the bad arm. The bad arm is also trained each day for several weeks. This study will test the ability of pediatric CI therapy to improve motor function in children with cerebral palsy.


Options:
A: Arm Label: rTMS and CIMT; Type: EXPERIMENTAL; Interventions: Procedure: Repetitive Transcranial Magnetic Stimulation (rTMS), Procedure: Constraint-induced movement therapy (CIMT) | Arm Label: rTMS and no CIMT; Type: EXPERIMENTAL; Interventions: Procedure: Repetitive Transcranial Magnetic Stimulation (rTMS) | Arm Label: Sham and CIMT; Type: EXPERIMENTAL; Interventions: Procedure: Constraint-induced movement therapy (CIMT) | Arm Label: Sham and no CIMT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Repetitive Transcranial Magnetic Stimulation (rTMS); Assigned to Arm(s): rTMS and CIMT, rTMS and no CIMT | Intervention Type: PROCEDURE; Name: Constraint-induced movement therapy (CIMT); Assigned to Arm(s): Sham and CIMT, rTMS and CIMT
B: Intervention Type: BEHAVIORAL; Name: Pediatric Constraint-Induced Movement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Conventional pediatric motor rehabilitation therapy; Assigned to Arm(s): N/A
C: Arm Label: Real rTMS combined with CIT; Type: EXPERIMENTAL; Interventions: Device: real rTMS combined with constraint induced therapy | Arm Label: Sham rTMS combined with CIT; Type: SHAM_COMPARATOR; Interventions: Device: sham rTMS combined with constraint induced therapy | Intervention Type: DEVICE; Name: real rTMS combined with constraint induced therapy; Assigned to Arm(s): Real rTMS combined with CIT | Intervention Type: DEVICE; Name: sham rTMS combined with constraint induced therapy; Assigned to Arm(s): Sham rTMS combined with CIT
D: Arm Label: Treatment dosage levels examined; Type: EXPERIMENTAL; Interventions: Other: Therapy services (ACQUIREc Therapy) | Intervention Type: OTHER; Name: Therapy services (ACQUIREc Therapy); Assigned to Arm(s): Treatment dosage levels examined

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Maternal to Infant HIV Transmission in India
Brief Summary: Infants who are breast-fed by HIV infected mothers have an increased risk of becoming infected with HIV. Standard therapy for the prevention of HIV infections in infants included zidovudine (ZDV) prior to the onset of labor, a single dose of nevirapine (NVP) for women during labor, and a single dose of NVP for newborns given 72 hours after birth. This study will determine if giving low dose daily NVP to breastfed infants of HIV infected mothers, in addition to standard therapy, will be more effective than standard therapy alone at preventing HIV infections in these infants.


Options:
A: Intervention Type: DRUG; Name: Zidovudine/Lamivudine and either Nevirapine or Nelfinavir; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding for 6 months postpartum; Assigned to Arm(s): N/A
B: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine and mulitvitamins | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine and mulitvitamins | Intervention Type: DRUG; Name: Nevirapine and mulitvitamins; Assigned to Arm(s): 1, 2
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combined short-course zidovudine/nevirapine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: HAART | Intervention Type: DRUG; Name: Combined short-course zidovudine/nevirapine; Assigned to Arm(s): B | Intervention Type: DRUG; Name: HAART; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Maternal to Infant HIV Transmission in India
Brief Summary: Infants who are breast-fed by HIV infected mothers have an increased risk of becoming infected with HIV. Standard therapy for the prevention of HIV infections in infants included zidovudine (ZDV) prior to the onset of labor, a single dose of nevirapine (NVP) for women during labor, and a single dose of NVP for newborns given 72 hours after birth. This study will determine if giving low dose daily NVP to breastfed infants of HIV infected mothers, in addition to standard therapy, will be more effective than standard therapy alone at preventing HIV infections in these infants.


Options:
A: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2
C: Arm Label: Abrupt Weaning; Type: EXPERIMENTAL; Interventions: Other: abrupt weaning at 4 months | Arm Label: Exclusive breastfeeding per WHO guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: Continued exclusive breastfeeding | Intervention Type: OTHER; Name: abrupt weaning at 4 months; Assigned to Arm(s): Abrupt Weaning | Intervention Type: OTHER; Name: Continued exclusive breastfeeding; Assigned to Arm(s): Exclusive breastfeeding per WHO guidelines
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine and mulitvitamins | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine and mulitvitamins | Intervention Type: DRUG; Name: Nevirapine and mulitvitamins; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.


Options:
A: Arm Label: ACU-4429 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: ACU-4429 5 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: ACU-4429 10 mg; Type: EXPERIMENTAL; Interventions: Drug: ACU-4429 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACU-4429; Assigned to Arm(s): ACU-4429 10 mg, ACU-4429 2.5 mg, ACU-4429 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Ozanimod1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Interferon β-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ozanimod placebo, Drug: Interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg | Intervention Type: DRUG; Name: Ozanimod placebo; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a placebo; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.


Options:
A: Arm Label: Open Label; Type: EXPERIMENTAL; Interventions: Drug: Pegaptanib Sodium 0.3 mg | Intervention Type: DRUG; Name: Pegaptanib Sodium 0.3 mg; Assigned to Arm(s): Open Label
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: C